Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2023 Earnings Call Transcript

David Roth: Yes. I think that the latter is the case. We do our very best over time when a trial initiates with all kinds of ways to project enrolment rates based on the number of sites that are activated and the delivery of active sites to the trial. And as you get closer and closer to the finish line, the data are more robust in terms of the accuracy of how they lead us to come to our predictions. So now that there’s light at the end of the tunnel, I think we’re feeling very, very confident that we can project completing the enrolment for the primary endpoint that 198 patient should be delivered in the first quarter of the year. And since it’s just a little different than what we previously said, we just thought it was appropriate to update that at this time.

Operator: And there are no further questions at this time. I would like to turn it back to Dr. Nancy Simonian for closing remarks.

Nancy Simonian: Thank you, operator and thank you, everyone, for joining us today. I am deeply grateful for the opportunity to start up and lead Syros over the past 11 years. I am proud of the achievements we made together and I’m excited about the potential for tamibarotene to transform the lives of patients. I look forward to Syros’ next chapter on the path to commercialization and continuing my service as a member of the Board. Finally and importantly, I want to express my thanks to you, our investors and analysts and the entire Syros team for your support over the years. It truly makes a difference for patients. Thank you.

Operator: Thank you, presenters. And ladies and gentlemen, this concludes today’s conference call. Thank you for participating. You may now disconnect.